Close
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of
Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous
This is a Phase 2, randomized, active-controlled, parallel-group, multisite, open-label studyof belzutifan plus fulvestrant versus everolimus plus ETPC (fulvestrant or exemestane) inparticipants with ER+/HER2- unresectable, locally advanced, or mBC.
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
This is a Phase 3, global, multicenter, randomized, open-label study.
Cancer patients are getting younger. Mays Cancer Center experts explain the modern factors at play
The risk of aging-related diseases, including cancer, doesn't sharply increase until the age of 50. Why then are so many younger people getting cancer right now?
Promising compound kills range of hard-to-treat cancers
Ratna Vadlamudi, PhD, a professor of obstetrics and gynecology at the Mays Cancer Center, is researching compounds that can target cancer cells to stop their growth.
S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Bre
This clinical trial aims to validate the results observed in I-SPY2 and will test if adding durvalumab to neoadjuvant chemotherapy can increase pCR rates, shift residual cancer burden to lower values and improve invasive breast cancer free survival in early-stage HRpositive MP2 cancers.
The role of genetic testing in cancer prevention and treatment
Discover how genetic testing at the Mays Cancer Center can guide cancer prevention and treatment. Learn about DNA analysis, personalized risk management, and family implications, as our expert counselors support your journey to proactive, informed cancer care.
Siblings in remission race to honor everyday cancer heroes – and each other
More than $80,000 was raised during this year's Give Cancer the Boot Survivorship 5K and 1-Mile Walk to support cancer patients and their families. For survivors, the race was about something more personal: celebrating life, one step at a time.
Meet the Mays Cancer Center's newest providers
We're thrilled to introduce four exceptional new doctors to our cancer center team! Their broad expertise and dedication make them ready to provide top-notch care and innovative treatments. Read to learn more about their impressive backgrounds and how they'll enhance our patient services.